Avalo Therapeutics, Inc. (AVTX)

Last Closing Price: 16.35 (2026-05-22)

Net Income (Annual)

Net Income: Company's net profit or loss after all revenues, income items, and expenses have been accounted for. Because this figure is given after preferred dividend expense, it is the net income value allotted to common shareholders.

Avalo Therapeutics, Inc. (AVTX) had Net Income of $-78.26M for the most recently reported fiscal year, ending 2025-12-31.

Figures for fiscal year ending 2025-12-31
Income Statement Financials
$0.06M
Net Income
$-78.26M
--
$0.06M
$72.98M
$-72.92M
$-5.17M
$-78.09M
$-78.09M
$-78.26M
$-78.26M
$-78.26M
$-78.26M
$-72.92M
$-72.58M
13.40M
13.40M
$-5.84
$-5.84
Balance Sheet Financials
$105.29M
$0.46M
$11.17M
$116.46M
$12.94M
--
$20.47M
$33.41M
$83.05M
$72.55M
$83.05M
18.51M
Cash Flow Statement Financials
$-51.46M
$-81.72M
$14.59M
$134.70M
$16.11M
$-118.59M
$13.62M
--
--
Fundamental Metrics & Ratios
8.14
--
--
--
--
100.00%
-123601.70%
-123601.70%
-123018.60%
-132362.70%
-132642.40%
$-51.46M
--
--
--
0.00
--
--
--
-94.23%
-107.87%
-67.20%
-94.23%
$4.49
$-3.84
$-3.84